EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Microbiota-driven therapeutic efficacy of Hyperoside in ulcerative colitis and associated anxiety

Li Yin, Lin Xu, Yu-Nan Shan, Zhilin He, Yanbin Li, Wei Chen

Frontiers in Cellular and Infection Microbiology · 29.01.2026 · 16

DOI: 10.3389/fcimb.2026.1734356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 29.01.2026. Verfasst von Li Yin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Quercetin, Anxiety, Colitis, Ulcerative, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ulcerative colitis (UC) is subtype of inflammatory bowel disease that is frequently comorbid with anxiety disorders. However, effective dual-targeting therapies are still lacking. Hyperoside (HYP), a natural flavonoid, exhibits anti-inflammatory and neuroprotective properties, yet its potential therapeutic effects on UC and associated anxiety, as well as the underlying mechanisms, remain largely unexplored.

Methods

A murine model of DSS-induced colitis was established and treated with HYP. Disease activity was assessed through body weight, colon length, and histopathology. Anxiety-like behaviors were evaluated using open field and elevated plus maze tests. Neuroinflammation was examined through immunohistochemistry of BDNF expression and microglial activation. Gut microbiota composition was profiled by metagenomic sequencing, and metabolomic profiling was conducted using the Q300 Kit. Network pharmacology and molecular docking were employed to predict signaling pathways, which were further validated by Western blotting. Additionally, antibiotic depletion experiments were conducted to determine microbiota dependency.

Results

HYP administration significantly ameliorated DSS-induced colitis, as evidenced by attenuated weight loss, restored colon length, and improved histopathology. It suppressed pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and restored intestinal barrier integrity by upregulating Mucin-2 and ZO-1. Furthermore, HYP also alleviated anxiety-like behaviors and mitigated neuroinflammation by increasing BDNF levels and suppressing microglial activation. HYP treatment also restored gut microbial homeostasis, enriching beneficial bacteria such as Enterobacter ludwigii while reducing the abundance of Enterobacter hormaechei, Escherichia coli , and Acinetobacter baumannii . Metabolomic analysis revealed that HYP significantly promoted arginine biosynthesis. Network pharmacology and molecular docking identified the MAPK, PI3K-Akt, and NF-κB pathways as potential targets, with HYP showing strong binding affinity to MAPK3, AKT1, and NFκB1. Importantly, the therapeutic effects of HYP were abolished in microbiota-depleted mice.

Conclusion

Our findings demonstrate that HYP effectively alleviates DSS-induced colitis and comorbid anxiety-like behaviors. Its efficacy is dependent on the gut microbiota and is associated with the restoration of microbial homeostasis, enhancement of arginine metabolism, and modulation of the MAPK/PI3K-Akt/NF-κB signaling pathways. HYP represents a promising microbiota-targeting therapeutic candidate for UC and its neuropsychiatric comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuercetinAnxietyColitis, UlcerativeGastrointestinal MicrobiomeAnimalsMiceDisease Models, AnimalMolecular Docking SimulationMaleSignal TransductionCytokinesColonMice, Inbred C57BLMetabolomicsAnti-Inflammatory AgentsDextran SulfateNetwork PharmacologyNF-kappa B

Stichwörter der Autor:innen

MAPK/PI3K-Akt/NF-κB signaling pathwaysanxietyarginine biosynthesisgut microbiotagut-brain axishyperosideulcerative colitis

Substanzen

QuercetinhyperosideCytokinesAnti-Inflammatory AgentsDextran SulfateNF-kappa B

Autor:innen und Institutionen

  • Department of Gastroenterology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • School of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
  • Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Institute of Neuroimmunology, Shandong Key Laboratory of Rheumatic Disease…

Zitieren

APA

Yin, L., Xu, L., Shan, Y. N., He, Z., Li, Y., & Chen, W. (2026). Microbiota-driven therapeutic efficacy of Hyperoside in ulcerative colitis and associated anxiety. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1734356

Vancouver

Yin L, Xu L, Shan YN, He Z, Li Y, Chen W. Microbiota-driven therapeutic efficacy of Hyperoside in ulcerative colitis and associated anxiety. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1734356

BibTeX
@article{Yin2026,
  author = {Yin, Li and Xu, Lin and Shan, Yu-Nan and He, Zhilin and Li, Yanbin and Chen, Wei},
  title = {Microbiota-driven therapeutic efficacy of Hyperoside in ulcerative colitis and associated anxiety},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1734356}
}
Kostenlos starten →